Side-by-side · Research reference

HexarelinvsSNAP-8

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 1HUMAN-REVIEWED19/45 cited

BHuman-MechanisticHUMAN-REVIEWED8/46 cited

Hexarelin

Hexapeptide GHRP · Cardio-tropic

100–200 mcgPer doseSmith 1996

Phase 1Evidence levelGhigo 1997

~70 minHalf-lifeSemenistaya 2010

SQ · Multiple sites · 1–3×/day

SNAP-8

Synthetic Octapeptide · Cosmetic Topical

TopicalRoute

8-AAPeptide length

SNAREPrimary target

Topical · Facial application · Twice daily

01Mechanism of Action

Parameter

Hexarelin

SNAP-8

Primary target

Ghrelin receptor (GHS-R1a) + cardiac CD36Smith 1996 Ghigo 1997

SNARE complex (SNAP-25 competitive binding site)

Pathway

GHS-R1a → Gαq → Ca²⁺ → GH release. CD36 engagement → direct cardio-tropic actionGhigo 1997

Acetyl octapeptide-3 → SNARE complex disruption → Reduced vesicular fusion → Decreased acetylcholine release → Muscle relaxation

Downstream effect

Strong GH pulse + IGF-1 elevation; cardio-protective effects in animal MI modelsGhigo 1997

Transient reduction in neuromuscular signal transmission, decreased muscle contraction amplitude, wrinkle depth reduction

Feedback intact?

Yes initially; tachyphylaxis with chronic useGhigo 1997

N/A — topical cosmetic, no systemic endocrine axis

Origin

Synthetic hexapeptide His-D-2-Methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂Smith 1996

Synthetic peptide derived from N-terminal fragment of SNAP-25 protein (synaptosomal-associated protein 25 kDa)

Antibody development

—

02Dosage Protocols

Parameter

Hexarelin

SNAP-8

Standard dose

100–200 mcg per injectionSmith 1996

—

Frequency

1–2× per day max (tachyphylaxis with chronic 3× daily)

—

Lower / starter dose

50 mcg per dose

—

Evidence basis

Phase 1 / Phase 2 trialsSmith 1996 Ghigo 1997

RCT, in vitro skin penetration studies

Duration

4–8 weeks on / 4–8 weeks off (tachyphylaxis mitigation)

—

Reconstitution

Bacteriostatic water

—

Timing

Pre-sleep + fasted preferred

—

Half-life

~70 minSemenistaya 2010

—

Typical concentration

—

2–10% in cosmetic formulationsLupin 2024 Raikou 2017

Commercial products typically use 5–10%.

Application frequency

—

Twice daily (morning and evening)Lupin 2024

Treatment duration

—

20–60 days for visible effectRaikou 2017

Skin microtopography improvements measured at 20-day intervals.

Formulation type

—

Oil-in-water emulsion, serum, cream

Application site

—

Facial skin — glabellar lines, crow's feet, forehead

Onset of effect

—

Visible reduction in wrinkle depth by day 20–28Raikou 2017

03Metabolic / Fat Loss Evidence

04Side Effects & Safety

Parameter

Hexarelin

SNAP-8

Cortisol elevation

Modest at high dosesGhigo 1997

—

Prolactin elevation

Modest at high dosesGhigo 1997

—

Hunger

Strong appetite increase via ghrelin agonism

—

Tachyphylaxis

Receptor desensitisation with chronic dosingGhigo 1997

—

Cardiac effects

Direct cardio-tropic; potential benefit in MI but unstudied in humansGhigo 1997

—

IGF-1 elevation

Strong; monitor with chronic high-dose use

—

Cancer risk

Contraindicated in active malignancy (GH/IGF-1 axis)

—

Pregnancy / OB

Avoid

—

Cytotoxicity

—

Concentration-dependent antiproliferative effect observed in vitro; IC50 ~10 mg/mL (argireline, 6-AA analogue)

Commercial formulations typically use 0.05–0.1 mg/mL, well below cytotoxic threshold.

Skin irritation

—

Minimal; well-tolerated in clinical use

Peptide oxidation

—

Methionine residue susceptible to oxidation in formulation; may reduce efficacyKluczyk 2021

Formulation stability issue, not a direct adverse effect.

Systemic absorption

—

Negligible; peptide remains in stratum corneum and epidermisKraeling 2015

Hypersensitivity

—

Rare; no widespread allergic reactions reported

Absolute Contraindications

Hexarelin

·Active malignancy
·Pregnancy / breastfeeding
·Disrupted hypothalamic-pituitary axis

SNAP-8

·Known hypersensitivity to acetyl octapeptide-3 or formulation excipients

Relative Contraindications

Hexarelin

·Untreated diabetes
·Severe hyperprolactinemia

SNAP-8

·Active skin infections or open wounds at application site
·Neuromuscular disorders (theoretical concern, no documented cases)

05Administration Protocol

Parameter

Hexarelin

SNAP-8

1. Reconstitution

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL = 250 mcg per 0.1 mL.

Wash face with gentle cleanser and pat dry. Remove makeup and surface oils to optimize peptide contact.

2. Injection site

SQ — abdomen or thigh. Rotate sites.

Apply 1–2 drops or pea-sized amount of SNAP-8 serum or cream to target areas (forehead, glabellar lines, crow's feet). Gently massage until absorbed.

3. Timing

Pre-sleep + fasted preferred. Cycle on/off to avoid tachyphylaxis.

Twice daily — morning and evening. Allow 2–3 minutes for absorption before applying additional skincare products.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

Apply before heavier creams or occlusive moisturizers. Peptides penetrate best from water-based serums on clean skin.

5. Needle

29–31G, 4–8 mm insulin syringe.

Store at room temperature, away from direct sunlight. Refrigeration may extend shelf life of formulations containing unstable peptides.

6. Duration

—

Consistent use for 20–60 days required for visible wrinkle reduction. Effects are temporary and reverse upon discontinuation.

06Stack Synergy

Hexarelin

+ CJC-1295 (no DAC)

Strong

View CJC-1295 (no DAC) →

Hexarelin (GHRP) + CJC-1295-no-DAC (GHRH analogue) is the higher-amplitude variant of the standard GHRH+GHRP stack. Hexarelin produces a stronger pulse than ipamorelin but with cortisol + prolactin signal — choose this stack for maximum GH amplitude when side-effect tolerance is acceptable. Cycle aggressively.

Hexarelin: 100 mcg SQ · pre-sleep
CJC-1295 (no DAC): 100 mcg SQ · same injection
Primary benefit: Maximum GH pulse amplitude (with side-effect signal)

Smith 1996 Teichman 2006

SNAP-8

— no documented stacks